DPP-4 inhibitors are known to increase vascular leakage by augmenting the SDF-1α/VE-cadherin signaling pathway[12] and cause angioedema.[13] In this case, SDF-1α appears to be correlated with the severity of systemic capillary permeability. The gene discussed is CXCL12; the disease is angioedema.